Prevalence of high-risk individuals for breast/ovarian cancer in a general Iranian female population using the International Breast Cancer Intervention Study (IBIS) risk calculation tool

Document Type : Original Article

Authors

1 Department of Obstetrics and Gynecology, Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Internist, Iran University of Medical Science, Tehran, Iran

3 Obstetrician and Gynecologist, Fellowship of laparoscopy, Tehran University of Medical Sciences, Tehran, Iran

4 Department of Obstetrics and Gynecology, Mahdieh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

5 Department of Obstetrics and Gynecology, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Objectives: Various risk assessment tools have been developed to evaluate the risk of hereditary breast/ovarian cancer. This study aims to estimate the risk of breast/ovarian cancer in a sample of the general population in Iran using the IBIS software.
Methods: A total of 2020 women aged 18-79 years were consecutively selected from the gynecology clinic of Imam Hossein Medical Center between April 2019 and 2021. The Tyrer-Cusick (IBIS) questionnaire was used to collect data on variables such as age, BMI, age at menarche, age at first pregnancy, menopausal status, history of hormone replacement therapy (HRT), and family history of breast/ovarian cancer. The risks of developing breast/ovarian cancer were calculated, with patients having a calculated risk of more than 20% considered high-risk and those below 20% considered low-risk.
Results: Out of the 2020 cases studied, 69 (3.4%) were classified as high-risk for developing breast/ovarian cancer. The moderate risk of breast/ovarian cancer in patients with a positive family history was 18.47%, compared to 10.15% in those without a family history. All high-risk individuals had a positive family history, while only 9.4% of the low-risk population had a family history; this difference was statistically significant (p<0.001).
Conclusion: Routine assessment of family history of cancer in all patients is recommended, with positive cases being further evaluated using a cancer risk assessment tool and referred for genetic counseling as appropriate.

Highlights

Maliheh Arab [Pubmed] [Google Scholar]

 

Keywords

Main Subjects

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. doi:10.3322/caac.21660 PMid:33538338
  2. Adib E, El Zarif T, Nassar AH, Akl EW, Abou Alaiwi S, Mouhieddine TH, et al. CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer. Br J Cancer. 2022;126(5):797-803. doi:10.1038/s41416-021-01673-7 PMid:34949788 PMCid:PMC8888603
  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi:10.3322/caac.21442 PMid:29313949
  4. Jones MR, Kamara D, Karlan BY, Pharoah PD, Gayther SA. Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. Gynecol Oncol. 2017;147(3):705-13. doi:10.1016/j.ygyno.2017.10.001 PMid:29054568
  5. Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol. 2010;28(3):387-91. doi:10.1200/JCO.2009.25.0712 PMid:20008623
  6. Nelson HD, Fu R, Goddard K, Mitchell JP, Okinaka-Hu L, Pappas M, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.
  7. Amiri-Moghadam Z. Frequency of Heart Involvement in Kawasaki Disease during a Decade in Iran. Novel Clin Med. 2022; 1(1): 50-54.
  8. Howell A, Astley S, Warwick J, Stavrinos P, Sahin S, Ingham S, et al. Prevention of breast cancer in the context of a national breast screening programme. J Intern Med. 2012;271(4):321-30. doi:10.1111/j.1365-2796.2012.02525.x PMid:22292490
  9. Onega T, Beaber EF, Sprague BL, Barlow WE, Haas JS, Tosteson AN, et al. Breast cancer screening in an era of personalized regimens: A conceptual model and National Cancer Institute initiative for risk‐based and preference‐based approaches at a population level. Cancer. 2014;120(19):2955-64. doi:10.1002/cncr.28771 PMid:24830599 PMCid:PMC4342235
  10. Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat. 1993;28(2):115-20. doi:10.1007/BF00666424 PMid:8173064
  11. US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005; 143(5):355-61. doi:10.7326/0003-4819-143-5-200509060-00011 PMid:16144894
  12. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13(11):1387. doi:10.7150/ijbs.21635 PMid:29209143 PMCid:PMC5715522
  13. Yildiz G, Selvi F, Bedel C, Zortuk O, Yavuz Y. Clinical significance of Tp-e interval, Tp-e/QT ratio, and Tp-e/QTc ratio in patients with renal colic. J Prev Complement Med. 2024; 3(1): 36-40. doi: 10.22034/ncm.2023.418250.1134
  14. Cunningham AP, Antoniou AC, Easton DF. Clinical software development for the Web: lessons learned from the BOADICEA project. BMC Med Inform Decis Mak. 2012;12(1). doi:10.1186/1472-6947-12-30 PMid:22490389 PMCid:PMC3507671
  15. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97 (22): 1652-62. doi:10.1093/jnci/dji372 PMid:16288118
  16. Force UPST. Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 319(6):588-94. doi:10.1001/jama.2017.21926 PMid:29450531
  17. Stevanato KP, Pedroso RB, Iora P, Dos Santos L, Pelloso FC, de Melo WA, et al. Comparative analysis between the Gail, Tyrer-Cuzick and BRCAPRO models for breast cancer screening in Brazilian population. Asian Pac J Cancer Prev. 2019;20(11):3407. doi:10.31557/APJCP.2019.20.11.3407 PMid:31759366 PMCid:PMC7063010
  18. Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(1):77-102. doi:10.6004/jnccn.2021.0001 PMid:33406487
  19. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Prev Biomarkers. 2012 ;21(1): 134-47.
  20. Himes DO, Root AE, Gammon A, Luthy KE. Breast cancer risk assessment: calculating lifetime risk using the Tyrer-Cuzick model. J Nurse Pract. 2016;12(9):581-92. doi:10.1016/j.nurpra.2016.07.027
  21. Gagnon J, Lévesque E, Borduas F, Chiquette J, Diorio C, Duchesne N, et al. Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies. Curr Oncol. 2016;23 (6): 615-25. doi:10.3747/co.23.2961 PMid:28050152 PMCid:PMC5176389
  22. Bharucha PP, Chiu KE, François FM, Scott JL, Khorjekar GR, Tirada NP. Genetic Testing and Screening Recommendations for Patients with Hereditary Breast Cancer. RadioGraphics. 2020; 40(4):913-36. doi:10.1148/rg.2020190181 PMid:32469631
  23. Wang X, Huang Y, Li L, Dai H, Song F, Chen K. Assessment of performance of the Gail model for predicting breast cancer risk: a systematic review and meta-analysis with trial sequential analysis. Breast Cancer Res. 2018;20(1):1-9. doi:10.1186/s13058-018-0947-5 PMid:29534738 PMCid:PMC5850919
  24. Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Canc Netw. 2017;15(1):9-20. doi:10.6004/jnccn.2017.0003 PMid:28040716
  25. Lee MV, Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, et al. BRCA-associated cancers: role of imaging in screening, diagnosis, and management. Radiographics. 2017; 37(4):1005-23. doi:10.1148/rg.2017160144 PMid:28548905
  26. Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654. doi:10.1200/JCO.2011.39.8545 PMid:22711857 PMCid:PMC3413277
  27. Gao Q, Tomlinson G, Das S, Cummings S, Sveen L, Fackenthal J, et al. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet. 2000;107(2):186-91. doi:10.1007/s004390000290 PMid:11030417
  28. Chavarri-Guerra Y, Blazer KR, Weitzel JN. Genetic cancer risk assessment for breast cancer in Latin America. Revista de investigacion clinica. 2017;69(2):94-102. doi:10.24875/RIC.17002195 PMid:28453507 PMCid:PMC5658001
  29. Society AC. American Cancer Society. Recommendations for the Early Detection of Breast Cancer. https://wwwcancerorg/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancerhtml. 2021.
International Archives of Health Sciences
Volume 11, Issue 2
April 2024
Pages 115-121

Files

History

  • Receive Date: 07 August 2023
  • Revise Date: 22 March 2024
  • Accept Date: 29 March 2024

Share

How to cite

Statistics